This is the authors' abstract. We don't add key points for this paper.
AIC246 (letermovir) is a potent anticytomegalovirus drug in clinical development. Here, we report a consistent antiviral efficacy of AIC246 against human cytomegalovirus laboratory strains, clinical isolates, and virus variants resistant to approved drugs. Furthermore, we describe a remarkable selectivity of AIC246 for human cytomegaloviruses compared to that of other alpha-, beta-, or gammaherpesviruses or nonrelated pathogenic viruses, including adeno-, hepadna-, retro-, orthomyxo-, and flaviviruses. Our data confirm and support an excellent and selective anticytomegaloviral activity of AIC246.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Marschall et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: